Suppr超能文献

多点热传感器与冷冻消融术后改善肿瘤学结局相关。

Multipoint Thermal Sensors Associated with Improved Oncologic Outcomes Following Cryoablation.

作者信息

Martin Jeremy W, Patel Roshan M, Okhunov Zhamshid, Vyas Aashay, Vajgrt Duane, Clayman Ralph V

机构信息

1 Department of Urology, University of California , Irvine, Irvine, California.

2 Department of Radiology, University of California , Irvine, Irvine, California.

出版信息

J Endourol. 2017 Apr;31(4):355-360. doi: 10.1089/end.2016.0864. Epub 2017 Feb 17.

Abstract

INTRODUCTION

Cryoablation (CA) is a minimally invasive modality for the management of small renal cortical neoplasms (RCN). Effective ablation is dependent on achieving target temperatures during CA that result in tumor cell death. We investigated long-term oncologic outcomes following CA using multipoint thermal sensors (MTS), which allow precise temperature determination at four points along the needle.

METHODS

We performed a retrospective review of 20 patients with <4 cm RCN who underwent de novo CA from 2005 to 2009. In 11 procedures, MTS needles were deployed with the goal of obtaining -20°C at the tumor margin, while 9 were done without MTS. Patient demographics, tumor characteristics, and CA procedure data were retrieved and analyzed. Follow-up CT or MRI was used to assess recurrence status.

RESULTS

With a mean follow-up of 45 months, none of the 11 patients experienced a recurrence in the MTS group, compared with 4 of 9 (44.4%) patients in the non-MTS group (p = 0.026). Of the biopsy-confirmed renal cancers, none of the 6 in the MTS group, compared with 3 of 6 (50%) in the non-MTS group, recurred (p = 0.182). Age, tumor size, surgical approach, tumor histopathology, grade, follow-up time, and skin-to-tumor distance were similar between the MTS and non-MTS groups. The MTS group was also associated with increased total length of freeze (p = 0.041), procedure time (p = 0.020), cryoprobe utilization (p = 0.049), and a greater ratio of cryoprobes used per cm diameter of tumor (p = 0.003).

CONCLUSIONS

In this small renal mass pilot study, the use of MTS needles to monitor temperature and guide cryoneedle deployment was associated with improved oncologic outcomes.

摘要

引言

冷冻消融术(CA)是一种用于治疗小肾皮质肿瘤(RCN)的微创方法。有效的消融取决于在冷冻消融过程中达到导致肿瘤细胞死亡的目标温度。我们使用多点热传感器(MTS)研究了冷冻消融术后的长期肿瘤学结局,该传感器可在针的四个点精确测定温度。

方法

我们对2005年至2009年接受初治冷冻消融术的20例肾肿瘤直径<4 cm的患者进行了回顾性研究。在11例手术中,使用MTS针的目的是使肿瘤边缘达到-20°C,而9例手术未使用MTS。检索并分析患者的人口统计学、肿瘤特征和冷冻消融手术数据。采用随访CT或MRI评估复发情况。

结果

平均随访45个月,MTS组11例患者均未复发,而非MTS组9例患者中有4例(44.4%)复发(p = 0.026)。在活检确诊的肾癌中,MTS组6例均未复发,而非MTS组6例中有3例(50%)复发(p = 0.182)。MTS组和非MTS组在年龄、肿瘤大小、手术方式、肿瘤组织病理学、分级、随访时间以及皮肤至肿瘤距离方面相似。MTS组还与冷冻总时长增加(p = 0.041)、手术时间增加(p = 0.020)、冷冻探针使用量增加(p = 0.049)以及每厘米肿瘤直径使用的冷冻探针比例更高(p = 0.003)相关。

结论

在这项小肾肿块的初步研究中,使用MTS针监测温度并指导冷冻针的放置与改善肿瘤学结局相关。

相似文献

1
Multipoint Thermal Sensors Associated with Improved Oncologic Outcomes Following Cryoablation.
J Endourol. 2017 Apr;31(4):355-360. doi: 10.1089/end.2016.0864. Epub 2017 Feb 17.
3
Real-time magnetic resonance imaging-guided cryoablation of small renal tumors at 1.5 T.
Invest Radiol. 2013 Jun;48(6):437-44. doi: 10.1097/RLI.0b013e31828027c2.
4
Laparoscopic renal cryoablation using ultrathin 17-gauge cryoprobes: mid-term oncological and functional results.
BJU Int. 2011 Aug;108(4):577-82. doi: 10.1111/j.1464-410X.2010.09807.x. Epub 2010 Nov 2.
5
Percutaneous cryoablation of solitary sporadic renal cell carcinomas.
BJU Int. 2012 Dec;110(11 Pt B):E526-31. doi: 10.1111/j.1464-410X.2012.11230.x. Epub 2012 May 15.
6
Percutaneous cryoablation of anterior renal masses: technique, efficacy, and safety.
AJR Am J Roentgenol. 2010 Dec;195(6):1418-22. doi: 10.2214/AJR.09.3530.
8
Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.
World J Urol. 2017 Apr;35(4):633-640. doi: 10.1007/s00345-016-1911-6. Epub 2016 Aug 2.
10
Percutaneous Cryoablation of Clinical T2 (> 7 cm) Renal Masses: Technical Considerations, Complications, and Short-Term Outcomes.
J Vasc Interv Radiol. 2015 Jun;26(6):800-6. doi: 10.1016/j.jvir.2015.02.013. Epub 2015 Mar 31.

引用本文的文献

1
Breast Cancer Cryoablation: Assessment of the Impact of Fundamental Procedural Variables in an In Vitro Human Breast Cancer Model.
Breast Cancer (Auckl). 2020 Nov 12;14:1178223420972363. doi: 10.1177/1178223420972363. eCollection 2020.
2
Skin-to-tumor Distance Predicts Treatment Failure of T1A Renal Cell Carcinoma Following Percutaneous Cryoablation.
Urology. 2017 Oct;108:195-200. doi: 10.1016/j.urology.2017.06.026. Epub 2017 Jun 23.

本文引用的文献

1
Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.
J Urol. 2016 Oct;196(4):989-99. doi: 10.1016/j.juro.2016.04.081. Epub 2016 May 6.
2
Cryoablation for Small Renal Masses: Selection Criteria, Complications, and Functional and Oncologic Results.
Eur Urol. 2016 Jan;69(1):116-28. doi: 10.1016/j.eururo.2015.03.027. Epub 2015 Mar 26.
3
Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses.
Eur Urol. 2015 Feb;67(2):252-9. doi: 10.1016/j.eururo.2014.07.021. Epub 2014 Aug 6.
5
Ablative therapies for small renal tumours.
Nat Rev Urol. 2013 May;10(5):284-91. doi: 10.1038/nrurol.2013.68. Epub 2013 Apr 23.
6
Incomplete thermal ablation stimulates proliferation of residual renal carcinoma cells in a translational murine model.
BJU Int. 2012 Sep;110(6 Pt B):E281-6. doi: 10.1111/j.1464-410X.2012.11261.x. Epub 2012 May 22.
7
Tumour in solitary kidney: laparoscopic partial nephrectomy vs laparoscopic cryoablation.
BJU Int. 2012 Jan;109(1):118-24. doi: 10.1111/j.1464-410X.2011.10287.x. Epub 2011 Sep 2.
8
Ablative therapies for renal tumors.
Ther Adv Urol. 2010 Apr;2(2):51-68. doi: 10.1177/1756287210366708.
9
Optimal freeze cycle length for renal cryotherapy.
J Urol. 2011 Jul;186(1):283-8. doi: 10.1016/j.juro.2011.03.034. Epub 2011 May 20.
10
Cryoprobe isotherms: a caveat and review.
J Endourol. 2010 May;24(5):673-6. doi: 10.1089/end.2009.0435.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验